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Both hospital and outpatient products, as well as orphan drugs have been included in 
this analysis. All medicinal products have been assessed on the INN level, without 
differentiating original, innovative products from generics. In addition to general sta-
tistical analysis, the GDP adjusted comparison has also been performed. Subsequently 
we have also conducted more detailed analysis of the following ATC groups, known 
to be major health care cost drivers: C (cardiovascular), J (anti-infective), L (oncology), 
M (musculo-skeletal) and N (neurology, psychiatry). RESULTS: As expected, linear 
correlation between national GDP and number of reimbursed INNs have been 
observed. However, major differences in mentioned ATC groups have revealed the 
inconsistency of the current HTA activities across countries leading to sometimes 
unfair treatment possibilities for patients with different diseases which could have not 
been justiﬁed by unequal socio-economic characteristics of investigated countries. 
CONCLUSIONS: There is a strong need for the continuous education of national 
decision makers on the principles and processes of the HTA. New innovative ideas of 
ﬁnancing the health care in developing countries are urgently needed in order to ensure 
ethical standards in health care and subsequent patient access to cost effective treat-
ment, but at the same time to engage patients in investing in their personal health and 
wellbeing.
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OBJECTIVES: Since the 1990s, many articles have documented problems with US 
payers’ utilization of pharmacoeconomic studies for decision-making. By replicating 
an in-depth survey methodology, this study aimed to determine the extent to which 
US practices had changed over the past decade. METHODS: Semi-structured explor-
atory interviews were conducted in 2007 to develop a survey instrument—ﬁelded 
in 2007–08 with key formulary decision-makers at US insurers and US public payers 
in 9 pre-identiﬁed categories. The structured set of questions examined US health 
care payers’ 1) use of, and attitudes and perceptions regarding, pharmacoeconomic 
information, and 2) opinions about how pharmaceutical manufacturers present 
pharmacoeconomic information. RESULTS: Compared to 10 years ago, U.S. payers 
regard pharmacoeconomic information much more favorably, despite variation in their 
use of and attitudes toward pharmacoeconomics. Payers cluster in three groups: a 
minority who use pharmacoeconomic information frequently and rigorously; a broader 
group who examine pharmacoeconomic information informally and do rigorous analy-
sis occasionally; and a group who only review pharmacoeconomic information in 
broad terms along with other drug-related information. Across all categories, payers 
acknowledge that the quality of pharmacoeconomic studies has improved. Payers 
suggest that pharmacoeconomic studies often “answer the wrong questions”—e.g., by 
failing to identify the subset(s) of patients where the drug is most effective. Payers 
remain skeptical towards pharmacoeconomic information and studies provided/spon-
sored by industry—e.g., when they perceive companies present only favorable studies. 
Increasingly, payers separate clinical reviews from pharmacoeconomic evaluations; the 
latter may be integrated with rebating discussions. CONCLUSIONS: US payer atti-
tudes about and use of pharmacoeconomic information have improved; however, 
formal, rigorous use of cost-effectiveness analysis is not the norm. Most payers 
foresee their organizations using pharmacoeconomic evaluation slightly more and 
would welcome a neutral entity that produced pharmacoeconomic evidence—although 
some question whether even government funding could insulate it from industry and 
political inﬂuence.
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OBJECTIVES: Social Health Insurance (SHI) and National Health Service (NHS) are 
two main choices for health reform. China’s health reform during last decade is basi-
cally SHI-oriented, especially after the implementation of “Basic health Insurance 
of Urban Workers” since 1998. Theoretically speaking, a NHS system will invest 
more on preventive care than an SHI system. This research investigates the effect of 
increasing health insurance coverage on health expenditure in China, especially 
through the speciﬁc channel of preventive care. METHODS: We estimates the health 
care expenditure function with province-level panel data from 1991–2007 of China. 
The key determinates we examined are social health insurance policy implication (the 
increaseing coverage of health insurance) and the share of preventive care in health 
disbursement. Other determinants are those usually in literatures including GDP, 
doctor and beds supply, population, aging. The independent variables of interests 
are per capita health expenditure, hospitalization expenses, inspecting commission 
and medical expenses. A generalized difference-in-difference method is used to assess 
the effect of adoption of social health insurance. IV methods are used to control 
the possible endogeneity problems. RESULTS: The increasing coverage of health 
insurance is expected to contribute to health care expenditure increasing. The more 
is the spending of preventive health care, the lower the health expenditure is. More-
over, we ﬁnd social health insurance coverage has a crowding-out effect on preventive 
care expenditure. Other variables’ effects are similar to the results from literatures. 
CONCLUSIONS: “Low accessibility and high costs in health care service” is key 
problem of China’s health care system right now. The SHI oriented health reform 
is a driver of health care expenditure increasing. China has just stated of a new 
comprehensive heath care system reform. The move to SHI may be politically correct, 
but is not the best option for China. It will lead to long-term and deep crisis in the 
health sector.
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OBJECTIVES: To estimate the hospitalisation cost of ICU patients admitted to the 
TUHL in the region of Thessaly, in Greece.        METHODS: The ICU chosen is the only 
tertiary university ICU in the whole region of Thessaly accounting 27% of the total 
ICU beds. The study sample consisted of all patients (elective and emergency admis-
sions) admitted to the respective TUHL in 2006. Clinical data were derived from    
patients’ medical records on a retrospective basis whereas economic data were derived 
from the Hospital’s Financial Department. The analysis included direct costs, using 
an up-down approach under NHS perspective. The nominal and actual hospitalization 
cost per ICU patient were based on the resource utilisation and the annual hospital 
balance sheets on NHS prices in Euros. RESULTS: 312 have been admitted to the 
ICU with a total direct cost of a4,799 million suffering from stroke, COPD, cancer,  
heart, trauma, pneumonia with a mean length of stay 8.87 days. The mean cost per 
hospitalisation day in the ICU was estimated at a1,734. Mean actual cost per patient 
is estimated at a15,382 whereas social insurance funds reimburse only a1,666. Person-
nel costs are the major cost component accounting for 31% of the total cost, while 
the pharmaceuticals account for 23%, laboratory 11%, supply and oxygen 17%, 
infrastructure-hotel services expenses 18%. CONCLUSIONS: This research results in 
some meaningful conclusions for effecting changes in hospital policies for better utili-
zation of ICU resources, for optimizing patient care and incorporating economic  
assessment in decision-making.
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OBJECTIVES: The objective of the study is to obtain behaviour of the cost’s relative 
average weights of the assistance with the retrospective application of the Adjusted 
Clinical Groups (ACG’s) in 16 teams of Primary Care with an attended population 
in the clinical practice use.   METHODS: Multicentre, retrospective study based on 
electronic records of patients seeking care during 2008 in the regions of Aragon, 
Balears and Catalonia. Main measurements: universal variables (age, sex, health 
service-family practice/paediatrics) and dependent variables: episodes and total       
cost (visits, diagnostic test, referrals, drugs). The ACG case-mix System software 
(version 7.1; N  106) classiﬁed subjects into a single category for a given annual           
resource consumption. The model of cost per each patient was established differencing         
the ﬁx cost and the variable. Outlier patients were considered those surpassing 
T  Q31.5(Q3-Q1)  a1,778.6 for total cost expenditure. Log transformation of 
the dependent variable was carried out to reduce skewness of the distribution and           
make it close to normal. Explanatory power was calculated by coefﬁcients of deter-
mination (R2). Statistical software: SPSS, p  0.05. RESULTS: The total number of 
the studied patients was 227,235 (intensity of use: 75.6%), with an average 4.5         o 3.2 
episodes. The age average was of 44.1 o 23.7 years, 56.6% women (13.5% paediat-
rics). The distribution of costs was a148,657,137. The total unitary cost per patient/
year 654.2 o 851.7a (relative weights of reference). Patient’s case-mix: 57.2% of 
the study population was grouped into 10 ACG. The explanatory power of the 
ACG classiﬁcation system was 36.3% (Ln: 41.2%), p  0,001. 6.2% of patients    
were considered Outliers (N  14.066). It details the form skewness and the average         
relative weights per each category of ACG’s classiﬁcation. CONCLUSIONS: The 
ACG are an acceptable system of classiﬁcation of patients in situation of clinical 
practice use. Some ACG classiﬁcation categories should be separeted due to the high        
outliers number.
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OBJECTIVES: To study how concentrated the Finnish pharmaceutical market is in 
certain medicine groups. During the last decade the Finnish authorities have imple-
mented different acts to increase the competition in the pharmaceutical market.     
